Ashwin N. Ananthakrishnan
Experienced in Nonalcoholic Steatohepatitis (NASH)

Dr. Ashwin N. Ananthakrishnan

Gastroenterology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Experienced in Nonalcoholic Steatohepatitis (NASH)
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ashwin Ananthakrishnan is a Gastroenterologist in Boston, Massachusetts. Dr. Ananthakrishnan is rated as an Experienced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Colonoscopy, and Endoscopy. Dr. Ananthakrishnan is currently accepting new patients.

His clinical research consists of co-authoring 424 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in WI
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
North Shore Medical Center -
Cooley Dickinson Hospital Inc,the
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunshine Health
  • EPO
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114
Other Locations
MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
102 Endicott St, Mgh North Shore Medical, Danvers, MA 01923

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome
A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Other
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: TAK-018
Study Phase: Phase 2
GI Complications in Cancer Immunotherapy Patients
GI Complications in Cancer Immunotherapy Patients
Enrollment Status: Unknown
Publish Date: April 05, 2022
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

422 Total Publications

Where Are You From?
Where Are You From?
Journal: JAMA
Published: September 25, 2025
Similar Doctors
Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Thomas A. Capozza
Gastroenterology | Hepatology
Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Thomas A. Capozza
Gastroenterology | Hepatology
289 Pleasant St, Bldg 4, Suite 501, 
Fall River, MA 
 (46.1 miles away)
508-679-6611
Languages Spoken:
English

Thomas Capozza is a Gastroenterologist and a Hepatologist in Fall River, Massachusetts. Dr. Capozza is rated as a Distinguished provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Visceromegaly, Cirrhosis, Endoscopy, and Gastrectomy.

Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Stephen Zucker
Gastroenterology
Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Stephen Zucker
Gastroenterology

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (2.7 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Zucker is a Gastroenterologist in Boston, Massachusetts. Dr. Zucker is rated as a Distinguished provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Macroamylasemia, Hepatitis, Endoscopy, and Liver Transplant.

Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Maria A. Catana
Gastroenterology
Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Maria A. Catana
Gastroenterology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (2.5 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maria Catana is a Gastroenterologist in Boston, Massachusetts. Dr. Catana is rated as a Distinguished provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). Her top areas of expertise are Fibrolamellar Carcinoma, Alcoholic Cirrhosis, Visceromegaly, Ascites, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ananthakrishnan's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile